Search

Your search keyword '"Laperche, S"' showing total 518 results
Start Over Author "Laperche, S"
518 results on '"Laperche, S"'

2. Impact of recent criteria changes for the deferral criteria specific to men who have sex with men in France.

Author

Sauvage, Claire, Laperche, S., Corominas, V., Stefic, K., Le Cam, S., Pouchol, É., Morel, P., Tiberghien, P., and Lot, F.

Subjects
*HEPATITIS C virus, *MEN who have sex with men, *HEPATITIS B virus, *HIV, *BLOOD donors
Abstract

Background and Objectives: In 2016, France allowed men who have sex with men (MSM) to donate blood if they had not had sex with men in the previous 12 months. In April 2020, this restriction was relaxed to 4 months due to the lack of negative impact observed on blood safety. This study assesses the impact of reducing this deferral period on epidemiological surveillance indicators. Materials and Methods: This study compares infection surveillance indicators between two 30‐month periods before (P1) and after (P2) this second deferral change. Results: Overall, 79 donations tested positive for human immunodeficiency virus (HIV) (49 in P1 and 30 in P2), 322 for hepatitis C virus (HCV) (185 and 137), 622 for hepatitis B virus (HBV) (355 and 267) and 1684 for syphilis (799 and 885). Positive donation rates decreased between P1 and P2, except for syphilis: HIV (0.07/10,000 donations vs. 0.04; p > 0.5), HCV (0.25 vs. 0.20; p < 0.05), HBV (0.49 vs. 0.39; p < 0.01) and syphilis (1.10 vs. 1.29; p < 0.001). For all three viruses, residual risks of transmission by transfusion did not increase: HIV (1/7,800,000 donations vs. 1/10,500,000), HCV (1/25,200,000 vs. 1/47,300,000) and HBV (1/6,400,000 vs. 1/6,000,000). Conclusion: Reducing the deferral period for MSM in April 2020 did not negatively impact residual risks, which remained very low, or the rate of positive donations, except for syphilis, which requires careful monitoring. To ensure equal access to blood donation, MSM have been allowed to donate blood under the same conditions as other donors since March 2022 (i.e., no more than one sexual partner in the last 4 months). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Screening for transfusion transmissible infections using rapid diagnostic tests in Africa: a potential hazard to blood safety?

Author

Prugger, C, Laperche, S, Murphy, EL, Bloch, EM, Kaidarova, Z, Tafflet, M, Lefrère, J-J, and Jouven, X

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Hepatitis - C, Emerging Infectious Diseases, Chronic Liver Disease and Cirrhosis, Liver Disease, Prevention, Infectious Diseases, Clinical Research, Digestive Diseases, Hepatitis, HIV/AIDS, 4.2 Evaluation of markers and technologies, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Infection, Good Health and Well Being, Africa, Blood Safety, Diagnostic Tests, Routine, HIV Infections, Hepatitis B, Hepatitis C, Humans, Mass Screening, Serologic Tests, blood transfusion, hepatitis B, hepatitis C, HIV, rapid diagnostic test, Clinical Sciences, Medical Physiology, Cardiovascular System & Hematology, Clinical sciences
Abstract

Rapid diagnostic tests (RDTs) are routinely used in African blood centres. We analysed data from two cross-sectional studies representing 95 blood centres in 29 African countries. Standardized panels of sera containing varying concentrations of anti-human immunodeficiency virus (HIV) antibodies (Ab), hepatitis B virus antigen (HBsAg) and antihepatitis C virus (HCV) Ab were screened using routine operational testing procedures at the centres. Sensitivity of detection using RDTs was high for HIV Ab-positive samples, but low for intermediately HBsAg (51·5%) and HCV Ab (40·6%)-positive samples. These findings suggest that current RDT use in Africa could pose a hazard to blood safety.

Published
2016

10. A pilot external quality assurance study of transfusion screening for HIV, HCV and HBsAG in 12 African countries

Author

Bloch, EM, Shah, A, Kaidarova, Z, Laperche, S, Lefrere, J‐J, Hasselt, J, Zacharias, P, Murphy, EL, and Group, the Anglophone Africa Transfusion Research

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Clinical Sciences, Prevention, Digestive Diseases, Infectious Diseases, Liver Disease, Clinical Research, HIV/AIDS, Emerging Infectious Diseases, Hepatitis, Hepatitis - C, Infection, Good Health and Well Being, Africa, Antibodies, Viral, Antigens, Viral, Blood Safety, Blood Transfusion, Donor Selection, HIV Infections, Hepatitis B, Hepatitis B Surface Antigens, Hepatitis C, Humans, Immunoenzyme Techniques, Laboratories, Pilot Projects, Quality Assurance, Health Care, Sensitivity and Specificity, blood transfusion, hepatitis B surface antigens, hepatitis C antibodies, HIV, laboratory proficiency testing, Anglophone Africa Transfusion Research Group, Blood transfusion, Hepatitis B surface antigens, Hepatitis C antibodies, Laboratory proficiency testing, Medical Physiology, Cardiovascular System & Hematology, Clinical sciences
Abstract

Background and objectivesSerologic screening for the major transfusion transmissible viruses (TTV) is critical to blood safety and has been widely implemented. However, actual performance as measured by proficiency testing has not been well studied in sub-Saharan Africa. Therefore, we conducted an external quality assessment of laboratories engaged in transfusion screening in the region.Materials and methodsBlinded test panels, each comprising 25 serum samples that were pedigreed for HIV, HBsAg, HCV and negative status, were sent to participating laboratories. The panels were tested using the laboratories' routine donor screening methods and conditions. Sensitivity and specificity were calculated, and multivariable analysis was used to compare performance against mode of testing, country and infrastructure.ResultsA total of 12 African countries and 44 laboratories participated in the study. The mean (range) sensitivities for HIV, HBsAg and HCV were 91·9% (14·3-100), 86·7% (42·9-100) and 90·1% (50-100), respectively. Mean specificities for HIV, HBsAg and HCV were 97·7%, 97% and 99·5%, respectively. After adjusting for country and infrastructure, rapid tests had significantly lower sensitivity than enzyme immunoassays for both HBsAg (P

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results